Loading
MAPK3 (Mitogen-activated protein kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signalling cascade initiated by activated KIT and KITLG/SCF.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.97, genetic association 0.00, clinical 0.19).
In plain words · MAPK3 (Mitogen-activated protein kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
MAPK3 (Mitogen-activated protein kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade.
No product in this corpus aims at MAPK3 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA MAPK3: RNA low tissue specificity; blood lineage lineage enriched (granulocytes 49 nTPM); high antibody staining in 12 normal tissues; highest cancer staining colorectal cancer (12 of 12 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas MAPK3 tissue; Open Targets ENSG00000102882 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Owaki et al, Biochem. Biophys. Res. Commun, 1992, "Extracellular signal-regulated kinases in T cells: characterization of human ERK1 and ERK2 cDNAs". Source.
Sources: HGNC HGNC:6877 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P27361 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000102882 (association with cancer (MONDO_0004992) 0.63; (GraphQL API, CC0))
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signalling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade also plays a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Location: Cytoplasm; Nucleus; Membrane, caveola; Cell junction, focal adhesion (UniProt). Locus 16p11.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: lineage enriched (granulocytes 49 nTPM).
Medium: Adrenal gland, Appendix, Bone marrow, Breast, Cervix, Duodenum, Endometrium, Epididymis.
Medium only: skin cancer.
HPA MAPK3 tissue · HPA MAPK3 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MAPK3" OR ABSTRACT:"MAPK3" OR TITLE:"mitogen-activated protein kinase 3" OR ABSTRACT:"mitogen-activated protein kinase 3" OR TITLE:"Mitogen-activated protein kinase 3" OR ABSTRACT:"Mitogen-activated protein kinase 3" OR TITLE:"ERK1" OR ABSTRACT:"ERK1" OR TITLE:"p44mapk" OR ABSTRACT:"p44mapk" OR TITLE:"p44erk1" OR ABSTRACT:"p44erk1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MAPK3, not a curated reading list.